Compare PRAA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PRAA | ANL |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | United States |
| Employees | 170 | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 639.1M | 731.6M |
| IPO Year | 2002 | 2022 |
| Metric | PRAA | ANL |
|---|---|---|
| Price | $17.53 | $10.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $24.50 | $20.00 |
| AVG Volume (30 Days) | ★ 872.1K | 108.2K |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $1,201,837,000.00 | N/A |
| Revenue This Year | $2.01 | $36.02 |
| Revenue Next Year | $2.53 | N/A |
| P/E Ratio | $21.73 | ★ N/A |
| Revenue Growth | ★ 7.83 | N/A |
| 52 Week Low | $10.25 | $0.88 |
| 52 Week High | $22.55 | $17.25 |
| Indicator | PRAA | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 45.81 |
| Support Level | $16.60 | $9.46 |
| Resistance Level | $17.78 | $12.59 |
| Average True Range (ATR) | 0.91 | 1.14 |
| MACD | 0.32 | 0.03 |
| Stochastic Oscillator | 99.59 | 47.86 |
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.